UA76406C2 - Use of 3-o-deacylated monophosphoryl lipid a or monophosphoryl lipid a in combination with gm-csf or il-12 as adjuvant combination in antigenic composition for enhancing immune response in vertebrate - Google Patents
Use of 3-o-deacylated monophosphoryl lipid a or monophosphoryl lipid a in combination with gm-csf or il-12 as adjuvant combination in antigenic composition for enhancing immune response in vertebrate Download PDFInfo
- Publication number
- UA76406C2 UA76406C2 UA2001128558A UA2001128558A UA76406C2 UA 76406 C2 UA76406 C2 UA 76406C2 UA 2001128558 A UA2001128558 A UA 2001128558A UA 2001128558 A UA2001128558 A UA 2001128558A UA 76406 C2 UA76406 C2 UA 76406C2
- Authority
- UA
- Ukraine
- Prior art keywords
- antigen
- mri
- peptide
- mice
- cells
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 154
- 239000002671 adjuvant Substances 0.000 title claims abstract description 146
- 230000000890 antigenic effect Effects 0.000 title claims abstract description 41
- 230000028993 immune response Effects 0.000 title claims abstract description 39
- 241000251539 Vertebrata <Metazoa> Species 0.000 title claims abstract description 24
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 title abstract description 4
- 229940035032 monophosphoryl lipid a Drugs 0.000 title abstract 4
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 title abstract 2
- 230000002708 enhancing effect Effects 0.000 title description 5
- 108091007433 antigens Proteins 0.000 claims abstract description 101
- 102000036639 antigens Human genes 0.000 claims abstract description 101
- 239000000427 antigen Substances 0.000 claims abstract description 99
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 226
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 81
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 47
- 241000700605 Viruses Species 0.000 claims description 28
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 15
- 239000013566 allergen Substances 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 229920001184 polypeptide Polymers 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 230000001717 pathogenic effect Effects 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 7
- 241000233866 Fungi Species 0.000 claims description 7
- 241000711920 Human orthopneumovirus Species 0.000 claims description 7
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims description 6
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 241000713311 Simian immunodeficiency virus Species 0.000 claims description 5
- 230000003211 malignant effect Effects 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 230000008021 deposition Effects 0.000 claims description 4
- 230000003071 parasitic effect Effects 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 abstract description 58
- 108090000695 Cytokines Proteins 0.000 abstract description 58
- 102000013462 Interleukin-12 Human genes 0.000 abstract description 3
- 108010065805 Interleukin-12 Proteins 0.000 abstract description 3
- 229940117681 interleukin-12 Drugs 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 192
- 238000002649 immunization Methods 0.000 description 112
- 210000004027 cell Anatomy 0.000 description 99
- 230000003053 immunization Effects 0.000 description 97
- 230000004044 response Effects 0.000 description 67
- 210000004989 spleen cell Anatomy 0.000 description 65
- 108090000623 proteins and genes Proteins 0.000 description 58
- 238000002474 experimental method Methods 0.000 description 55
- 235000018102 proteins Nutrition 0.000 description 54
- 102000004169 proteins and genes Human genes 0.000 description 54
- 238000004448 titration Methods 0.000 description 53
- 230000000694 effects Effects 0.000 description 42
- 210000002966 serum Anatomy 0.000 description 41
- 239000000839 emulsion Substances 0.000 description 30
- 230000035755 proliferation Effects 0.000 description 28
- 229960005486 vaccine Drugs 0.000 description 28
- 102000008070 Interferon-gamma Human genes 0.000 description 27
- 108010074328 Interferon-gamma Proteins 0.000 description 27
- 230000000638 stimulation Effects 0.000 description 27
- 239000012530 fluid Substances 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 21
- 210000000952 spleen Anatomy 0.000 description 20
- 229940044627 gamma-interferon Drugs 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 241001529936 Murinae Species 0.000 description 15
- 101710132190 Porin B Proteins 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 15
- 230000006698 induction Effects 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 230000003472 neutralizing effect Effects 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 101710204837 Envelope small membrane protein Proteins 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 101710145006 Lysis protein Proteins 0.000 description 13
- 230000028327 secretion Effects 0.000 description 13
- 102000008072 Lymphokines Human genes 0.000 description 12
- 108010074338 Lymphokines Proteins 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- 210000001217 buttock Anatomy 0.000 description 11
- 239000012228 culture supernatant Substances 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 10
- 229910052804 chromium Inorganic materials 0.000 description 10
- 239000011651 chromium Substances 0.000 description 10
- 241000282412 Homo Species 0.000 description 9
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 9
- 230000036755 cellular response Effects 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 241000282560 Macaca mulatta Species 0.000 description 8
- 102000016943 Muramidase Human genes 0.000 description 8
- 108010014251 Muramidase Proteins 0.000 description 8
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 229960003130 interferon gamma Drugs 0.000 description 8
- 229960000274 lysozyme Drugs 0.000 description 8
- 235000010335 lysozyme Nutrition 0.000 description 8
- 239000004325 lysozyme Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000006386 neutralization reaction Methods 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 241000725643 Respiratory syncytial virus Species 0.000 description 7
- 230000036436 anti-hiv Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 229940038774 squalene oil Drugs 0.000 description 7
- 229940104230 thymidine Drugs 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 241000212977 Andira Species 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 6
- 206010061598 Immunodeficiency Diseases 0.000 description 6
- 208000029462 Immunodeficiency disease Diseases 0.000 description 6
- 102100034349 Integrase Human genes 0.000 description 6
- 102000004388 Interleukin-4 Human genes 0.000 description 6
- 108090000978 Interleukin-4 Proteins 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000007813 immunodeficiency Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 229940028885 interleukin-4 Drugs 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 210000005087 mononuclear cell Anatomy 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 241000712461 unidentified influenza virus Species 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 5
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 5
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 210000002443 helper t lymphocyte Anatomy 0.000 description 5
- 230000028996 humoral immune response Effects 0.000 description 5
- 230000008348 humoral response Effects 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 244000045947 parasite Species 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 229940031439 squalene Drugs 0.000 description 5
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- 230000024932 T cell mediated immunity Effects 0.000 description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000009696 proliferative response Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000000405 serological effect Effects 0.000 description 4
- 230000003393 splenic effect Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 210000001215 vagina Anatomy 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 244000287680 Garcinia dulcis Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- 230000002788 anti-peptide Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- -1 but not limited to Proteins 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 101100153505 Caenorhabditis elegans tni-1 gene Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241000282553 Macaca Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000003941 amyloidogenesis Effects 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 235000019988 mead Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000016379 mucosal immune response Effects 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- XNTSZTNQFAPQDK-UHFFFAOYSA-N 2-methyl-3-(3-nitrophenyl)quinazolin-4-one;hydrochloride Chemical compound Cl.CC1=NC2=CC=CC=C2C(=O)N1C1=CC=CC([N+]([O-])=O)=C1 XNTSZTNQFAPQDK-UHFFFAOYSA-N 0.000 description 1
- QPILHXCDZYWYLQ-UHFFFAOYSA-N 2-nonyl-1,3-dioxolane Chemical compound CCCCCCCCCC1OCCO1 QPILHXCDZYWYLQ-UHFFFAOYSA-N 0.000 description 1
- 244000298715 Actinidia chinensis Species 0.000 description 1
- 235000009434 Actinidia chinensis Nutrition 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 102100025511 Anti-Muellerian hormone type-2 receptor Human genes 0.000 description 1
- 101710089052 Anti-Muellerian hormone type-2 receptor Proteins 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 101100152731 Arabidopsis thaliana TH2 gene Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 101100310222 Caenorhabditis briggsae she-1 gene Proteins 0.000 description 1
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 description 1
- 101100025824 Caenorhabditis elegans nas-3 gene Proteins 0.000 description 1
- 241000712083 Canine morbillivirus Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000723298 Dicentrarchus labrax Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000710803 Equine arteritis virus Species 0.000 description 1
- 241000711475 Feline infectious peritonitis virus Species 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
- 101710197836 HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 101000851593 Homo sapiens Separin Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 101710116852 Molybdenum cofactor sulfurase 1 Proteins 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 101100187130 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nim-1 gene Proteins 0.000 description 1
- 101800001776 Nuclear inclusion protein B Proteins 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 102100034574 P protein Human genes 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 240000002834 Paulownia tomentosa Species 0.000 description 1
- 235000010678 Paulownia tomentosa Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- 108010015724 Prephenate Dehydratase Proteins 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 101150033538 Rala gene Proteins 0.000 description 1
- 241000711897 Rinderpest morbillivirus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 235000014548 Rubus moluccanus Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229940125377 Selective β-Amyloid-Lowering Agent Drugs 0.000 description 1
- 102100036750 Separin Human genes 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000003181 encephalopathic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 208000010758 granulomatous inflammation Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002919 insect venom Substances 0.000 description 1
- 229940100602 interleukin-5 Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000001115 mace Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 238000009400 out breeding Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 102000007739 porin activity proteins Human genes 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000008001 rakum palm Nutrition 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000954 sacrococcygeal region Anatomy 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Beans For Foods Or Fodder (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13396399P | 1999-05-13 | 1999-05-13 | |
| PCT/US2000/013156 WO2000069456A2 (en) | 1999-05-13 | 2000-05-12 | Adjuvant combination formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA76406C2 true UA76406C2 (en) | 2006-08-15 |
Family
ID=22461127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2001128558A UA76406C2 (en) | 1999-05-13 | 2000-12-05 | Use of 3-o-deacylated monophosphoryl lipid a or monophosphoryl lipid a in combination with gm-csf or il-12 as adjuvant combination in antigenic composition for enhancing immune response in vertebrate |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US7611721B1 (et) |
| EP (1) | EP1178825B1 (et) |
| JP (2) | JP4974414B2 (et) |
| KR (1) | KR100863367B1 (et) |
| CN (1) | CN1192799C (et) |
| AT (1) | ATE516046T1 (et) |
| AU (1) | AU781469B2 (et) |
| BG (1) | BG106094A (et) |
| BR (1) | BR0010539A (et) |
| CA (2) | CA2767116A1 (et) |
| CZ (1) | CZ20013916A3 (et) |
| EA (1) | EA006233B1 (et) |
| EE (1) | EE200100597A (et) |
| ES (1) | ES2367625T3 (et) |
| GE (1) | GEP20053446B (et) |
| HR (1) | HRP20010839A2 (et) |
| HU (1) | HUP0201220A3 (et) |
| ID (1) | ID30407A (et) |
| IL (2) | IL146382A0 (et) |
| IS (1) | IS6156A (et) |
| MX (1) | MXPA01011499A (et) |
| NO (1) | NO20015523L (et) |
| NZ (1) | NZ515322A (et) |
| PL (1) | PL352312A1 (et) |
| SK (1) | SK16022001A3 (et) |
| TR (1) | TR200103266T2 (et) |
| UA (1) | UA76406C2 (et) |
| WO (1) | WO2000069456A2 (et) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9326174D0 (en) * | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
| WO2000069456A2 (en) | 1999-05-13 | 2000-11-23 | American Cyanamid Company | Adjuvant combination formulations |
| JP4164361B2 (ja) * | 2000-11-07 | 2008-10-15 | イムノワクチン テクノロジーズ インコーポレーテッド | 増強した免疫応答を有するワクチン、およびその調製方法 |
| HUP0600589A2 (en) | 2000-11-10 | 2006-11-28 | Wyeth Corp | Adjuvant combination formulations |
| CN106310293A (zh) | 2007-09-27 | 2017-01-11 | 免疫疫苗技术有限公司 | 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用 |
| CA2702058A1 (en) * | 2007-10-08 | 2009-04-16 | Intrexon Corporation | Engineered dendritic cells and uses for the treatment of cancer |
| AU2009253780B2 (en) | 2008-06-05 | 2014-08-14 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
| WO2011119920A2 (en) | 2010-03-25 | 2011-09-29 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| HUE037408T2 (hu) | 2011-06-10 | 2018-08-28 | Univ Oregon Health & Science | CMV glikoproteinek és rekombináns vektorok |
| GB201113570D0 (en) * | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
| EP2763698B1 (en) | 2011-10-06 | 2020-12-02 | ImmunoVaccine Technologies Inc. | Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof |
| RU2496149C1 (ru) * | 2012-06-19 | 2013-10-20 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") | Способ оценки противооспенной активности лечебно-профилактических препаратов |
| JP6980534B2 (ja) | 2015-06-25 | 2021-12-15 | ザ チルドレンズ メディカル センター コーポレーション | 造血幹細胞の増大、富化、および維持に関する方法および組成物 |
| AU2017235461B2 (en) | 2016-03-15 | 2023-02-23 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| US5078996A (en) | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
| US5939074A (en) | 1986-12-30 | 1999-08-17 | The United States Of America As Represented By The Department Of Health And Human Services | Multideterminant peptide antigens |
| US6294322B1 (en) | 1988-01-26 | 2001-09-25 | The United States Of America As Represented By The Department Of Health And Human Services | Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1 |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5013548A (en) | 1987-09-08 | 1991-05-07 | Duke University | Production of antibodies to HIV |
| US5019387A (en) | 1987-09-08 | 1991-05-28 | Duke University | Production of antibodies to HIV |
| US5993819A (en) | 1987-09-08 | 1999-11-30 | Duke University | Synthetic vaccine for protection against human immunodeficiency virus infection |
| US5223254A (en) | 1987-09-29 | 1993-06-29 | Praxis Biologics, Inc. | Respiratory syncytial virus: vaccines |
| CA1340506C (en) | 1987-11-24 | 1999-04-20 | Nicholas H. Carbonetti | Production of gonorrheal pi proteins and vaccines |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| DE68926859T2 (de) | 1988-11-10 | 1997-02-13 | Genetics Inst | Natürlicher killerzellen-stimulationsfaktor |
| US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| DE3934366A1 (de) | 1989-10-14 | 1991-04-18 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum |
| ATE153534T1 (de) | 1990-04-27 | 1997-06-15 | John Mcmichael | Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein |
| SE502569C2 (sv) * | 1991-05-31 | 1995-11-13 | British Tech Group | Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit |
| PT671947E (pt) | 1991-12-02 | 2000-07-31 | Univ Texas | Composicoes para produzir respostas de linfocitos t citotoxicas contra virus |
| US6037135A (en) | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
| CA2139756A1 (en) | 1992-07-08 | 1994-01-20 | Eric M. Bonnem | Use of gm-csf as a vaccine adjuvant |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| SG48309A1 (en) * | 1993-03-23 | 1998-04-17 | Smithkline Beecham Biolog | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a |
| US5637480A (en) | 1993-05-12 | 1997-06-10 | Genetics Institute, Inc. | DNA molecules encoding bone morphogenetic protein-10 |
| ATE196737T1 (de) | 1993-05-25 | 2000-10-15 | American Cyanamid Co | Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus |
| US5830877A (en) | 1993-08-26 | 1998-11-03 | The Regents Of The University Of California | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory |
| GB9326253D0 (en) * | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US5571515A (en) | 1994-04-18 | 1996-11-05 | The Wistar Institute Of Anatomy & Biology | Compositions and methods for use of IL-12 as an adjuvant |
| EP0762895B1 (en) | 1994-04-29 | 2002-08-07 | Duke University | Synthetic vaccine for protection against human immunodeficiency virus infection |
| AUPM543894A0 (en) | 1994-05-04 | 1994-05-26 | Commonwealth Scientific And Industrial Research Organisation | An adjuvant |
| WO1996010423A1 (en) | 1994-09-30 | 1996-04-11 | Ludwig Institute For Cancer Research | COMPOSITIONS CONTAINING A p53 DERIVED PROTEIN OR PEPTIDE, AN ADJUVANT, AND INTERLEUKIN-12 AND USES THEREOF |
| DE69534922T2 (de) | 1994-10-05 | 2006-11-23 | Vanderbilt University, Nashville | Interleukin-12 als adjuvans für paramyoxviridae impfstoffe |
| WO1996026277A1 (en) * | 1995-02-24 | 1996-08-29 | Cantab Pharmaceuticals Research Limited | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation |
| US6613337B1 (en) | 1997-02-12 | 2003-09-02 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of leishmaniasis |
| HUP9901039A2 (hu) | 1996-02-01 | 1999-07-28 | North American Vaccine, Inc. | Neisseria meningitidis B-csoportba tartozó külső-membrán-fehérjéjének (MB3) expressziója élesztőben, továbbá vakcinák |
| US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
| US5762943A (en) * | 1996-05-14 | 1998-06-09 | Ribi Immunochem Research, Inc. | Methods of treating type I hypersensitivity using monophosphoryl lipid A |
| JP3737519B2 (ja) | 1996-05-31 | 2006-01-18 | ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー | 百日咳菌ワクチン用アジュバントとしてのｉｌ―１２ |
| US6024965A (en) | 1996-10-18 | 2000-02-15 | Erasums University Rotterdam | Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection |
| AU729579B2 (en) * | 1996-10-23 | 2001-02-01 | Trustees Of The University Of Pennsylvania, The | Immunotherapy and improved vaccines |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| US6797276B1 (en) * | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
| US6350456B1 (en) * | 1997-03-13 | 2002-02-26 | Corixa Corporation | Compositions and methods for the prevention and treatment of M. tuberculosis infection |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| GB9711990D0 (en) * | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
| WO1998056415A1 (en) | 1997-06-11 | 1998-12-17 | Aquila Biopharmaceuticals, Inc. | Purified saponins as oral adjuvants |
| GB9712347D0 (en) * | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| JP2002509545A (ja) | 1997-07-08 | 2002-03-26 | カイロン コーポレイション | Ｄｎａワクチンを伴うサブミクロン水中油型エマルジョンの使用 |
| IS4518A (is) | 1997-07-09 | 1999-01-10 | Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group | Nýtt lyfjaform fyrir bóluefni |
| GB9717953D0 (en) * | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
| GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| EP1053016A2 (en) * | 1998-02-12 | 2000-11-22 | American Cyanamid Company | Vaccines comprising interleukin-12 and respiratory syncytial viral antigens |
| US6488936B1 (en) | 1998-02-12 | 2002-12-03 | Wyeth | Immunogenic composition of interleukin-12 (IL-12), alum, herpes simplex viral (HSV) antigen, and method thereof |
| CA2323929C (en) | 1998-04-03 | 2004-03-09 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| GB9907860D0 (en) | 1999-04-07 | 1999-06-02 | Smithkline Beecham Biolog | Novel compounds |
| WO2000069456A2 (en) | 1999-05-13 | 2000-11-23 | American Cyanamid Company | Adjuvant combination formulations |
-
2000
- 2000-05-12 WO PCT/US2000/013156 patent/WO2000069456A2/en not_active Application Discontinuation
- 2000-05-12 IL IL14638200A patent/IL146382A0/xx active IP Right Grant
- 2000-05-12 ES ES00930698T patent/ES2367625T3/es not_active Expired - Lifetime
- 2000-05-12 CZ CZ20013916A patent/CZ20013916A3/cs unknown
- 2000-05-12 SK SK1602-2001A patent/SK16022001A3/sk not_active Application Discontinuation
- 2000-05-12 GE GE4702A patent/GEP20053446B/en unknown
- 2000-05-12 US US10/009,473 patent/US7611721B1/en not_active Expired - Fee Related
- 2000-05-12 JP JP2000617916A patent/JP4974414B2/ja not_active Expired - Fee Related
- 2000-05-12 EP EP00930698A patent/EP1178825B1/en not_active Expired - Lifetime
- 2000-05-12 PL PL00352312A patent/PL352312A1/xx unknown
- 2000-05-12 AT AT00930698T patent/ATE516046T1/de not_active IP Right Cessation
- 2000-05-12 EA EA200101198A patent/EA006233B1/ru not_active IP Right Cessation
- 2000-05-12 TR TR2001/03266T patent/TR200103266T2/xx unknown
- 2000-05-12 EE EEP200100597A patent/EE200100597A/et unknown
- 2000-05-12 CA CA2767116A patent/CA2767116A1/en not_active Abandoned
- 2000-05-12 AU AU48473/00A patent/AU781469B2/en not_active Ceased
- 2000-05-12 MX MXPA01011499A patent/MXPA01011499A/es active IP Right Grant
- 2000-05-12 BR BR0010539-2A patent/BR0010539A/pt not_active Application Discontinuation
- 2000-05-12 NZ NZ515322A patent/NZ515322A/xx unknown
- 2000-05-12 CA CA2372181A patent/CA2372181C/en not_active Expired - Fee Related
- 2000-05-12 HU HU0201220A patent/HUP0201220A3/hu unknown
- 2000-05-12 ID IDW00200102377A patent/ID30407A/id unknown
- 2000-05-12 KR KR1020017014333A patent/KR100863367B1/ko not_active IP Right Cessation
- 2000-05-12 CN CNB008074895A patent/CN1192799C/zh not_active Expired - Fee Related
- 2000-12-05 UA UA2001128558A patent/UA76406C2/uk unknown
-
2001
- 2001-11-07 IL IL146382A patent/IL146382A/en not_active IP Right Cessation
- 2001-11-09 BG BG106094A patent/BG106094A/xx unknown
- 2001-11-12 IS IS6156A patent/IS6156A/is unknown
- 2001-11-12 NO NO20015523A patent/NO20015523L/no not_active Application Discontinuation
- 2001-11-12 HR HR20010839A patent/HRP20010839A2/hr not_active Application Discontinuation
-
2006
- 2006-08-08 US US11/501,904 patent/US20100233117A1/en not_active Abandoned
-
2011
- 2011-08-04 JP JP2011171095A patent/JP5230780B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8216595B2 (en) | Powerful vaccine composition comprising lipopeptide and poly I:C as an adjuvant | |
| JP4362049B2 (ja) | Ｄｎａ転写ユニットの接種による免疫化 | |
| US7981428B2 (en) | Flu vaccines and methods of use thereof | |
| JP5230780B2 (ja) | アジュバント混合製剤 | |
| WO1998022145A1 (en) | Immunization of infants | |
| JP5265545B2 (ja) | 免疫応答を誘発または誘導する方法 | |
| US20120107354A1 (en) | Viral vaccine and process for preparing the same | |
| KR20120131725A (ko) | 고병원성 조류인플루엔자 ａ ｈ５ｎ１ 바이러스 유사입자 및 이를 이용한 가금용 백신 | |
| Fairman et al. | Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study | |
| US20090087456A1 (en) | Adjuvanted vaccine | |
| Rehmani et al. | The influence of adjuvants on oral vaccination of chickens against Newcastle disease | |
| EP1250933A1 (en) | Vaccines including as an adjuvant high dose type I IFN | |
| JP4091152B2 (ja) | 金コロイドを含む核酸調製物 | |
| Uchida et al. | Application of surface-linked liposomal antigens to the development of vaccines that induce both humoral and cellular immunity | |
| US20060110740A1 (en) | Use of sendai virus as a human parainfluenza vaccine | |
| Ishihara et al. | Use of low toxicity adjuvants and killed virus to induce protective immunity against the Friend murine leukaemia retrovirus-induced disease | |
| Morein et al. | New ISCOMs meet unsettled vaccine demands | |
| US20230390384A1 (en) | Recombinant covid-19 vaccine composition comprising lipopeptide and poly (i:c) adjuvant, and use thereof | |
| Singh et al. | Immunogenicity and protective efficacy of virosome based vaccines against Newcastle disease | |
| WO2023230479A1 (en) | Combined vaccine containing infectious bronchitis virus attenuated massachusetts and recombinant lasota virus expressing arkansas spike | |
| US20150174236A1 (en) | Viral vaccine and process for preparing the same | |
| Hsieh | Approaches to enhance protection against infectious bursal disease in chickens conferred by DNA-mediated vaccination | |
| Becker et al. | The immune modulator adamantylamide dipeptide stimulates efficient MHC class I restricted responses in mice | |
| UA79426C2 (en) | Combined adjuvant compositions |